Everolimus As Second- or Third-line Treatment of Advanced Endometrial Cancer: ENDORAD, a Phase II Trial of GINECO

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Apr 25

PMID 23612453

Citations 40

Authors

I Ray-Coquard

L Favier

B Weber

C Roemer-Becuwe

P Bougnoux

M Fabbro

A Floquet

F Joly

A Plantade

D Paraiso

E Pujade-Lauraine

Affiliations

Soon will be listed here.

Abstract

Background: Patients with recurrent/metastatic endometrial cancer that progresses after chemotherapy have limited treatment options and poor outcomes. Preclinical data suggest the oral mammalian target of rapamycin inhibitor everolimus may provide clinical benefit in these patients.

Methods: In this multicenter, open-label, phase 2 study, patients with advanced or metastatic endometrial cancer refractory to one or two previous chemotherapy regimens received everolimus 10 mg per day until progression or unacceptable toxicity. Primary end point was the non-progressive disease rate at 3 months. Secondary end points included duration of response, progression-free, and overall survival (OS), and safety.

Results: Forty-four patients were enrolled (median age, 65 years); 66% received one previous chemotherapy regimen. The 3-month non-progressive disease rate was 36% (95% confidence interval 22-52%), including two patients (5%) with partial response (PR). At 6 months, two additional patients experienced PR. Median duration of response was 3.1 months. Median progression-free and OS were 2.8 months and 8.1 months, respectively. The most common adverse events were anaemia (100%), fatigue (93%), hypercholesterolaemia (81%), and lymphopenia (81%).

Conclusion: Everolimus demonstrated efficacy and acceptable tolerability in patients with chemotherapy-refractory advanced or metastatic endometrial cancer. These results support the further development of phosphatidylinositol 3-kinase-targeted therapies in endometrial cancer.

Citing Articles

Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research.

Son B, Lee W, Kim H, Shin H, Park H Cell Death Dis. 2024; 15(9):696.

PMID: 39349424 PMC: 11442590. DOI: 10.1038/s41419-024-07077-8.

High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options.

Matoba Y, Devins K, Milane L, Manning W, Mazina V, Yeku O Reprod Sci. 2024; 31(9):2541-2559.

PMID: 38658487 DOI: 10.1007/s43032-024-01544-5.

An eleven autophagy-related genes-based prognostic signature for endometrial carcinoma.

Li S, Pan J, Zhang Y, Tang Y, Zeng X, Wang S J Egypt Natl Canc Inst. 2022; 34(1):42.

PMID: 36210389 DOI: 10.1186/s43046-022-00135-2.

Patient benefit rate and guarantee time bias in analysis of outcomes for gynecologic oncology patients receiving targeted treatment after somatic tumor genetic testing.

Cathcart A, Chen E, Bruegl A Gynecol Oncol Rep. 2022; 42:101019.

PMID: 35719319 PMC: 9198318. DOI: 10.1016/j.gore.2022.101019.

Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer.

Wei W, Ban X, Yang F, Li J, Cheng X, Zhang R J Immunother Cancer. 2022; 10(5).

PMID: 35623659 PMC: 9150151. DOI: 10.1136/jitc-2021-004338.

References

Tredan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N . Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol. 2012; 8(4):243-51. DOI: 10.1007/s11523-012-0242-9. View

Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C . Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22 Suppl 6:vi35-9. DOI: 10.1093/annonc/mdr374. View

Sovak M, Dupont J, Hensley M, Ishill N, Gerst S, Abu-Rustum N . Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer. 2007; 17(1):197-203. DOI: 10.1111/j.1525-1438.2006.00746.x. View

Yao J, Shah M, Ito T, Bohas C, Wolin E, Van Cutsem E . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-23. PMC: 4208619. DOI: 10.1056/NEJMoa1009290. View

Podsypanina K, Lee R, Politis C, Hennessy I, Crane A, Puc J . An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A. 2001; 98(18):10320-5. PMC: 56959. DOI: 10.1073/pnas.171060098. View

Zhu A, Abrams T, Miksad R, Blaszkowsky L, Meyerhardt J, Zheng H . Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011; 117(22):5094-102. PMC: 3417818. DOI: 10.1002/cncr.26165. View

Milam M, Celestino J, Wu W, Broaddus R, Schmeler K, Slomovitz B . Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol. 2007; 196(3):247.e1-5. DOI: 10.1016/j.ajog.2006.10.872. View

Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Martin L . Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014; 135(2):184-9. DOI: 10.1016/j.ygyno.2014.06.033. View

Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K . Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One. 2012; 7(5):e37431. PMC: 3360787. DOI: 10.1371/journal.pone.0037431. View

10.

Schoffski P, Ray-Coquard I, Cioffi A, Bui N, Bauer S, Hartmann J . Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011; 12(11):1045-52. DOI: 10.1016/S1470-2045(11)70230-3. View

11.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

12.

Liu H, Scholz C, Zang C, Schefe J, Habbel P, Regierer A . Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 2012; 32(5):1627-37. View

13.

Hayes M, Wang H, Espinal-Witter R, Douglas W, Solomon G, Baker S . PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res. 2006; 12(20 Pt 1):5932-5. DOI: 10.1158/1078-0432.CCR-06-1375. View

14.

Rudd M, Price J, Fogoros S, Godwin A, Sgroi D, Merino M . A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 2011; 17(6):1331-40. PMC: 3060282. DOI: 10.1158/1078-0432.CCR-10-0540. View

15.

Creasman W, Odicino F, Maisonneuve P, Quinn M, Beller U, Benedet J . Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S105-43. DOI: 10.1016/S0020-7292(06)60031-3. View

16.

Humber C, Tierney J, Symonds R, Collingwood M, Kirwan J, Williams C . Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2006; 18(3):409-20. DOI: 10.1093/annonc/mdl417. View

17.

Slomovitz B, Lu K, Johnston T, Coleman R, Munsell M, Broaddus R . A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010; 116(23):5415-9. PMC: 5120730. DOI: 10.1002/cncr.25515. View

18.

Catasus L, DAngelo E, Pons C, Espinosa I, Prat J . Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod Pathol. 2010; 23(5):694-702. DOI: 10.1038/modpathol.2010.44. View

19.

Oza A, Elit L, Tsao M, Kamel-Reid S, Biagi J, Provencher D . Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011; 29(24):3278-85. PMC: 3158598. DOI: 10.1200/JCO.2010.34.1578. View

20.

Block M, Fister S, Emons G, Seeber S, Grundker C, Gunthert A . Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells. Anticancer Res. 2010; 30(6):2025-31. View